AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...

The stock's fall snapped a two-day winning streak.

AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor ...

Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...